Vulvar Cancer – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 25 PAGES: 49

Vulvar Cancer - Pipeline Review, H1 2012', provides an overview of the Vulvar Cancer therapeutic pipeline. This report provides information on the therapeutic development for Vulvar Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vulvar Cancer. 'Vulvar Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									                      Vulvar Cancer – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1925IDB
                                                                                              Publication Date: April 2012




Vulvar Cancer – Pipeline Review, H1 2012                                                      GMDHC1925IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Vulvar Cancer – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Vulvar Cancer Overview ..................................................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Vulvar Cancer..................................................................................................................... 8
Vulvar Cancer Therapeutics under Development by Companies ..................................................................................................... 10
Vulvar Cancer Therapeutics under Investigation by Universities/Institutes ...................................................................................... 11
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Vulvar Cancer Therapeutics – Products under Development by Companies ................................................................................... 16
Vulvar Cancer Therapeutics – Products under Investigation by Universities/Institutes .................................................................... 17
Companies Involved in Vulvar Cancer Therapeutics Development .................................................................................................. 18
    Merck & Co., Inc. ......................................................................................................................................................................... 18
    ISA Pharmaceuticals B.V. ........................................................................................................................................................... 19
Vulvar Cancer – Therapeutics Assessment...................................................................................................................................... 20
    Assessment by Monotherapy Products ....................................................................................................................................... 20
    Assessment by Combination Products ........................................................................................................................................ 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 26
    V503 - Drug Profile ...................................................................................................................................................................... 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Imiquimod - Drug Profile .............................................................................................................................................................. 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Tarceva - Drug Profile ................................................................................................................................................................. 28
         Product Description................................................................................................................................................................. 28
         Mechanism of Action ............................................................................................................................................................... 28
         R&D Progress ......................................................................................................................................................................... 28
    Avastin + Radiation Therapy - Drug Profile ................................................................................................................................. 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29



Vulvar Cancer – Pipeline Review, H1 2012                                                                                                           GMDHC1925IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Vulvar Cancer – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 29
    Docetaxel - Drug Profile .............................................................................................................................................................. 30
        Product Description................................................................................................................................................................. 30
        Mechanism of Action ............................................................................................................................................................... 30
        R&D Progress ......................................................................................................................................................................... 30
    Cisplatin + Radiation Therapy - Drug Profile ............................................................................................................................... 31
        Product Description................................................................................................................................................................. 31
        Mechanism of Action ............................................................................................................................................................... 31
        R&D Progress ......................................................................................................................................................................... 31
    Paclitaxel - Drug Profile ............................................................................................................................................................... 33
        Product Description................................................................................................................................................................. 33
        Mechanism of Action ............................................................................................................................................................... 33
        R&D Progress ......................................................................................................................................................................... 33
    Imiquimod + TA-CIN Vaccine - Drug Profile ................................................................................................................................ 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 35
    Triapine + Cisplatin + Radiation Therapy - Drug Profile .............................................................................................................. 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Topotecan - Drug Profile ............................................................................................................................................................. 38
        Product Description....................................................
								
To top